



U.S. Department of Justice
Federal Bureau of Prisons

Washington, D.C. 20534

NOV 24 2020

MEMORANDUM FOR CHIEF EXECUTIVE OFFICERS

FROM:

[Signature]
M. D. Smith, Assistant Director
Health Services Division

SUBJECT:

Waiver to Health Services Policies

This national policy waiver to 6020.01, 6190.04 and 6013.01 is in response to the COVID-19 epidemic and upcoming vaccination efforts.

P6030.01 Pharmacy Services Policy states:

a. **Pharmacy and Therapeutics (P&T) Committee.** The Clinical Director (CD) will establish a Pharmacy and Therapeutics (P&T) Committee that will meet at least quarterly.

P6190.04 Infectious Disease Management policy states:

■ The CD, HSA, ICO, and other appropriate institution staff will meet at least quarterly to review the implementation of the institution's infection control and surveillance program.

■ Evidence of, at a minimum, quarterly Infection Control meetings (minutes) and review of surveillance activities that are documented and included as part of the institution's Quality Improvement Program (QIP).

P6013.01 Health Services Quality Improvement states:

5. **QUALITY IMPROVEMENT (QI) METHODOLOGY.** The HSA will appoint a committee to systematically assess the QI at that institution. This committee should be interdisciplinary and include health care staff and staff from other departments and will meet at least quarterly.

8. **HEALTH SERVICES GOVERNING BODY.** The local Governing Body will meet at least quarterly but meetings may occur more frequently if deemed necessary.

11.c. **Multi-Level Mortality Review Report (BP-S563).** The

Mortality Review Committee will complete the Mortality Review Report in its entirety, and send it, accompanied by the original health record, to the Central Office, OQM within 30 days. Only a copy of the Mortality Review Report is to be sent to the appropriate Regional Director.

National policy waiver

Due to the COVID-19 pandemic and upcoming vaccination efforts, this national policy waiver is granted to allow:

- All quarterly Governing Body, Quality Improvement, Infection Control, and Pharmacy & Therapeutics meetings due during the period of this waiver are waived.
- Extend the time for multilevel mortality reviews to 90 days for general population institutions, 120 days for MRCs, and 180 days for Central Office / external mortality reviews.

This waiver is effective through March 31, 2021.

cc: Ken Hyle, Assistant Director/General Counsel, OGC
Louis Milusnic, Assistant Director, PRD

(b)(6); (b)(7)(C)

Regional Health Services Administrators
Medical Asset Support Team Members
HSD Branch Chiefs
HSD Chief Professional Officers